Maternal outcomes:
Six studies described a new diagnosis of preeclampsia after initiation of pravastatin treatment. Among women treated with pravastatin compared to control groups, the risk for the development of preeclampsia was non significantly decreased (OR=0.51, 95%CI:0.25–105, p=0.07, I=44%) (Figure 6).
In a sensitivity analysis that excluded Döbert et al study who selected women only in their late third trimester, The risk for the development of preeclampsia was significantly decreased (OR=0.37, 95%CI:0.18–0.74, p=0.01, I=0%) (Figure 7).